SE441753B - Sett att framstella en skyddad polypeptid med minskad benegenhet till immunicering och bibehallen fysiologisk aktivitet - Google Patents

Sett att framstella en skyddad polypeptid med minskad benegenhet till immunicering och bibehallen fysiologisk aktivitet

Info

Publication number
SE441753B
SE441753B SE7409366A SE7409366A SE441753B SE 441753 B SE441753 B SE 441753B SE 7409366 A SE7409366 A SE 7409366A SE 7409366 A SE7409366 A SE 7409366A SE 441753 B SE441753 B SE 441753B
Authority
SE
Sweden
Prior art keywords
physiological activity
polypeptime
immunization
diminished
prone
Prior art date
Application number
SE7409366A
Other languages
English (en)
Swedish (sv)
Other versions
SE7409366L (xx
Inventor
F F Davis
Es T Van
N C Palczuk
Original Assignee
Research Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Corp filed Critical Research Corp
Publication of SE7409366L publication Critical patent/SE7409366L/xx
Publication of SE441753B publication Critical patent/SE441753B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
    • C12N11/089—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
SE7409366A 1973-07-20 1974-07-18 Sett att framstella en skyddad polypeptid med minskad benegenhet till immunicering och bibehallen fysiologisk aktivitet SE441753B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38119173A 1973-07-20 1973-07-20

Publications (2)

Publication Number Publication Date
SE7409366L SE7409366L (xx) 1975-01-21
SE441753B true SE441753B (sv) 1985-11-04

Family

ID=23504063

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7409366A SE441753B (sv) 1973-07-20 1974-07-18 Sett att framstella en skyddad polypeptid med minskad benegenhet till immunicering och bibehallen fysiologisk aktivitet

Country Status (9)

Country Link
JP (1) JPS5623587B2 (xx)
CA (1) CA1033673A (xx)
CH (1) CH616942A5 (xx)
DE (1) DE2433883C2 (xx)
FR (1) FR2313939A1 (xx)
GB (1) GB1469472A (xx)
IL (1) IL45291A0 (xx)
NL (1) NL7409770A (xx)
SE (1) SE441753B (xx)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2930542A1 (de) * 1979-07-27 1981-02-12 Hoechst Ag Neue insulinderivate und verfahren zu ihrer herstellung
JPS58145691U (ja) * 1982-03-29 1983-09-30 株式会社タイト− テ−ブル型ビデオゲ−ム機
JPS5976288U (ja) * 1982-11-15 1984-05-23 大平技研工業株式会社 テ−ブル型テレビゲ−ム機
WO1985003934A1 (en) * 1984-03-06 1985-09-12 Takeda Chemical Industries, Ltd. Chemically modified protein and process for its preparation
JPS59204130A (ja) * 1983-04-30 1984-11-19 Nippon Chemiphar Co Ltd 新規プラスミノ−ゲンアクチベ−タ誘導体を含有してなる経口投与薬剤
DE3334407A1 (de) * 1983-09-23 1985-04-04 Hoechst Ag, 6230 Frankfurt In position b 30 modifizierte insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
JPH0327674Y2 (xx) * 1984-10-02 1991-06-14
JPS61163687U (xx) * 1985-03-28 1986-10-09
JPS62207485A (ja) * 1986-03-07 1987-09-11 大平技研工業株式会社 テレビゲ−ム機
US5037969A (en) * 1986-07-03 1991-08-06 Takeda Chemical Industries, Ltd. Glycosyl derivatives and use thereof
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5578496A (en) * 1991-12-19 1996-11-26 Board Of Regents, Baylor College Of Medicine Detection of autoantibodies associated with the disease myasthenia gravis
AU3423293A (en) * 1991-12-19 1993-07-19 Baylor College Of Medicine Pva or peg conjugates of peptides for epitope-specific immunosuppression
US5618528A (en) * 1994-02-28 1997-04-08 Sterling Winthrop Inc. Biologically compatible linear block copolymers of polyalkylene oxide and peptide units
US6541629B1 (en) * 1999-09-10 2003-04-01 The Procter & Gamble Company Enzyme inhibitors
US6323311B1 (en) 1999-09-22 2001-11-27 University Of Utah Research Foundation Synthesis of insulin derivatives
DK1578771T3 (da) * 2001-10-10 2013-06-10 Novo Nordisk As Remodellering og glycokonjugering af peptider
PT1436012T (pt) * 2001-10-18 2018-03-27 Nektar Therapeutics Conjugados poliméricos de antagonistas de opióides
BR0308710A (pt) * 2002-03-26 2007-01-09 Biosynexus Inc conjugados poliméricos antimicrobianos
US20040062748A1 (en) * 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
WO2004037310A2 (en) * 2002-10-21 2004-05-06 Allvivo, Inc. Surface coating comprising bioactive compound
CA2540138C (en) 2003-09-24 2013-07-30 Kyowa Hakko Kogyo Co., Ltd. Recombinant antibody against human insulin-like growth factor
US7790835B2 (en) 2003-12-03 2010-09-07 Nektar Therapeutics Method of preparing maleimide functionalized polymers
US20090042790A1 (en) * 2005-06-13 2009-02-12 Nastech Pharmaceutical Company Inc. Transmucosal delivery of peptide derivatives
US7301003B2 (en) * 2005-08-26 2007-11-27 Enzon Pharmaceuticals, Inc. Method of preparing polymers having terminal amine groups
US10046058B2 (en) * 2014-12-02 2018-08-14 Rezolute, Inc. Use of hydrophobic organic acids to increase hydrophobicity of proteins and protein conjugates
US20170342211A1 (en) * 2016-05-31 2017-11-30 Robert Bosch Gmbh Azlactone functionalized substrates for conjugation of biomolecules
EP4019007A1 (en) * 2016-06-01 2022-06-29 Servier IP UK Limited Formulations of polyalkylene oxide-asparaginase and methods of making and using the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE337223B (xx) * 1967-05-23 1971-08-02 Pharmacia Ab
US3619371A (en) * 1967-07-03 1971-11-09 Nat Res Dev Production of a polymeric matrix having a biologically active substance bound thereto
US3674767A (en) * 1967-07-14 1972-07-04 Nat Res Dev Novel polymeric materials containing triazinyl groups

Also Published As

Publication number Publication date
SE7409366L (xx) 1975-01-21
CH616942A5 (en) 1980-04-30
FR2313939B1 (xx) 1979-05-18
JPS5623587B2 (xx) 1981-06-01
NL7409770A (nl) 1975-01-22
CA1033673A (en) 1978-06-27
DE2433883C2 (de) 1986-03-27
FR2313939A1 (fr) 1977-01-07
JPS5042087A (xx) 1975-04-16
DE2433883A1 (de) 1976-02-05
GB1469472A (en) 1977-04-06
IL45291A0 (en) 1974-10-22

Similar Documents

Publication Publication Date Title
SE441753B (sv) Sett att framstella en skyddad polypeptid med minskad benegenhet till immunicering och bibehallen fysiologisk aktivitet
ES457050A1 (es) Un procedimiento para la preparacion de aminoacidos cicli- cos.
KR840002414A (ko) 아미노 기능이 부여된 아크릴 공중합체의 제조방법
ES411187A1 (es) Procedimiento para la preparacion de eteres heterociclicos.
JPS51139842A (en) Stabilizer for synthetic polymeric material
ATE107280T1 (de) Carbamoyl-2-pyrrolidinonverbindungen.
ES441678A1 (es) Un procedimiento de obtencion de nuevas composiciones poli- meras.
ES413926A1 (es) Un procedimiento para curar una resina curable al acido.
GR3018529T3 (en) Nematode vaccine.
ES429671A1 (es) Procedimiento para preparar n-metilcarbamatos de 2,3-dihidro-benzofuranilo(7) n-sulfenilados.
ES460621A1 (es) Procedimiento de sintesis de n-(1'-alil-2'-pirrolidilmetil)-2,3-dimetoxi-5-sulfamoilbenzamida.
DE3273145D1 (en) Virus vaccines and process for preparing the same
ES390778A1 (es) Un procedimiento para la fabricacion de fenilaminoalcanos.
ES378205A1 (es) Procedimiento para la preparacion de nuevos 2-amino-5-ni- trotiazoles sustituidos en el grupo amino.
ES452391A1 (es) Procedimiento para la preparacion de nuevas arilalcohilami- nas sustituidas.
FR2425429A1 (fr) N-cyano-azomethines utilisables pour la preparation d'antihistaminiques et leur preparation
SE7613536L (sv) Sett att framstella 3,4-disubstituerade 2-(beta-naftyl-oxi)-etylpyrazoloner och anvendning derav som lekemedel
GB1315670A (en) Pyrolysis of nickel salts of phosphonic acid monoesters
ES394637A1 (es) Procedimiento para estabilizar material organico posible dedegradacion oxidatica o termica.
JPS53147059A (en) Brominated cyclic ether having alkoxycarbonyl group and its preparation
JPS5424869A (en) Heterocyclic compounds and their preparation
JPS5340719A (en) Organophosphorus compound and chlorine-containing resin composition
JPS55154918A (en) Carcinostatic
ES289006A1 (es) Procedimiento para la preparación de polímeros estabilizados
ES432657A1 (es) Un metodo para la preparacion del isomero alfa del ester del acido palmitico de 10- (3- (4-hidroxietil-1-piperazinil)-propiliden) -2-trifluorometil-tiaxanteno.

Legal Events

Date Code Title Description
NUG Patent has lapsed

Ref document number: 7409366-7

Effective date: 19940810

Format of ref document f/p: F